cyrilzakka/clinical-trials huggingface dataset:
Characterization of the Use of Antipsychotics in Posttraumatic Stress Disorder During the Past Decade

The main purpose is to show the percentage of patients taking antipsychotics with PTSD by looking at approximately ten year's worth of data from 1994 through 2004. We will also determine the type and dose of antipsychotics the patients received, and to determine how many of those patients had psychotic versus nonpsychotic symptoms. We will be obtaining this data from the VISN 7 Corporate Data Warehouse. We hypothesize that there has been an overall increase in antipsychotic use in patient's with PTSD over the last 10 years.

This study is a retrospective chart review of patients, at the Tuscaloosa VA Medical Center, who were, treated with antipsychotics as monotherapy or adjunctive therapy.

The data will be retrieved from a computerized list of patients treated at the TVAMC for PTSD from 1994-2004 Charts will be reviewed by looking at approximately ten year's worth of data. Charts will then be examined to determine what type of antipsychotics patients were prescribed, the dose and duration of the antipsychotics, and the presence or absence of documented psychotic symptoms.

Eligibility Criteria:
Inclusion Criteria:

1. Have a diagnosis of PTSD (309.81)
2. Male or female patients at least 19 years of age

Exclusion Criteria:

• None
Microarray Analysis of Gene Expression in Idiopathic Pulmonary Fibrosis (IPF)

This study is investigating the way the lung is damaged in a condition called pulmonary fibrosis. Research studies will be conducted on lung tissue obtained from an open lung biopsy performed by the subject's surgeon. The identification of unique genetic markers of scarred lung may ultimately lead to new approaches to the diagnosis and treatment of pulmonary fibrosis.

Subjects are being asked to participate in a research study that is investigating the way the lung is damaged in a condition called pulmonary fibrosis. These research studies are conducted in the laboratory on a portion of the tissue from the subject's lung biopsy that was performed by a surgeon. The lung biopsy is to be performed for clinical purposes to diagnose the cause of the subject's lung disease. The tissue used for the research study will in no way interfere with the ability of the pathologist to establish a diagnosis. In addition, the results of your breathing tests, chest X-rays and CT scans, and diagnosis made from the lung biopsy (and slides) will be collected. The goal of the study is to gain an understanding of the causes of pulmonary fibrosis and why it gets worse, which may ultimately lead to new therapies for this disease. Once the lung biopsies are obtained, the pathologist will examine the tissue and determine if there is a sufficient amount available to use in the study without compromising their ability to make a diagnosis. If so, the lung biopsy will be divided. One portion will be submitted to the research study and the other processed by the pathologist in the usual manner to make a diagnosis. The decision to use tissue for the research study will be at the complete discretion of the pathologists. The tissue used in the study will be further processed in the laboratory in order to analyze for the presence of genetic markers in the scarred tissue that are not present in normal. The identification of these unique genetic markers of scarred lung may ultimately lead to new approaches to the diagnosis and treatment of pulmonary fibrosis.

Eligibility Criteria:
Inclusion Criteria:

* 18 years or age or older
* Diagnosis of pulmonary fibrosis
* Undergoing open lung biopsy

Exclusion Criteria:

* N/A
A Study of Semorinemab in Patients With Moderate Alzheimer's Disease

This Phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group study will evaluate the clinical efficacy, safety, pharmacokinetics, and pharmacodynamics of semorinemab in patients with moderate AD. The study consists of a screening period, a double-blind treatment period, an optional open-label extension (OLE) period, and a safety follow-up period. There may be up to two study cohorts.


Eligibility Criteria:
Inclusion Criteria:

* National Institute on Aging/Alzheimer's Association core clinical criteria for probable AD dementia
* Evidence of the AD pathological process, by a positive amyloid assessment either on CSF Aβ1-42 as measured on Elecsys β-Amyloid(1-42) Test System OR amyloid PET scan
* AD dementia of moderate severity, as defined by a screening MMSE score of 16-21 points, inclusive, and a CDR-GS of 1 or 2
* Availability of a person with sufficient contact with the participant to be able to provide accurate information on the participant's cognitive, behavioral and functional ability

Exclusion Criteria:

* Pregnant or breastfeeding
* Inability to tolerate MRI procedures or contraindication to MRI
* Contraindication to PET imaging
* Residence in a skilled nursing facility
* Any serious medical condition or abnormality in clinical laboratory tests that, in the investigator's judgment, precludes the patient's safe participation in and completion of the study, or bias the assessment of the clinical or mental status of the participant to a significant degree
* Any evidence of a condition other than AD that may affect cognition
* Substance abuse within the past 2 years
* Use of any experimental therapy within 90 days or 5 half-lives prior to screening, whichever is greater, or any passive immunotherapy against tau
* Use of any passive immunotherapy (immunoglobulin) against Aβ, unless the last dose was at least 1 year prior to screening or any active immunotherapy (vaccine) that is under evaluation to prevent or postpone cognitive decline
* Any other biologic therapy or previous treatment with medications specifically intended to treat Parkinsonian symptoms or any other non-AD neurodegenerative disorder within 1 year of screening
* Systemic immunosuppressive therapy within 12 months of screening through the entire study period
* Typical antipsychotic or neuroleptic medication within 6 months of screening
* Daily treatment with any of the following classes of medication (except for intermittent short-term use): opiates or opioids, benzodiazepines, barbiturates, hypnotics, or any medication with clinically significant centrally-acting antihistamine or anticholinergic activity
* Stimulant medications, unless the dose has been stable within the 6 months prior to screening and is expected to be stable throughout the study
Pain Relief Effect of Low-intensity Continuous Ultrasound Stimulator for Knee Arthritis

The goal of this clinical trial is to test low-intensity continuous ultrasound stimulator(LICUS) for patients suffering from knee arthritis. it aims to evaluate the pain relief effect of LICUS.

35 participants were recruited, treated by LICUS on the knee joint for 5 minutes, 3 times a day for 4 weeks.

This study has single group and is for a before and after comparison of clinical treatment.

Subject: 35 osteoarthritis patients Evaluation measure: Visual Analogue Scale (VAS), McMaster Universities Osteoarthritis Index (WOMAC) Method: A total of 35 subjects were selected in consideration of the dropout rate of 20%. Selected subjects were treated as a single group without randomization, and an appropriate amount of gel was applied to the knee OA pain area for 4 weeks. A blinded evaluation at baseline and after treat-ment was made. Primary outcome was pain on movement assessed by the VAS index. Secondary outcomes consisted of the WOMAC scores.

Eligibility Criteria:
Inclusion Criteria:

* Patients aged 40 to 60 years with pain due to OA of the knee and able to walk voluntarily
* Those who have more than one osteophyte in the tibiofemoral joint on radiographic findings (Kellgren-Lawrence gradesⅡ,Ⅲ)
* At visit 1 (screening) and visit 2, the pain status during knee OA activity was 100 mm pain VAS, as a result, those who are over 40mm
* If the Kellgren \& Lawrence Grades are the same, target the one with the higher 100mm pain VAS
* Patients who are willing or able to follow the doctor's instructions, including joint movements
* Persons who can comply with concomitantly permitted drugs, prohibited drugs, and relief drugs
* Persons who can maintain the same exercise and activity during the clinical trial period
* Fully understand the purpose and procedure of this clinical trial

Exclusion Criteria:

* Those who have a history of rheumatoid arthritis or gouty arthritis or who have peripheral pain other than the knee joint patient.
* Those with fractures or dislocations on simple radiological examination.
* Those who are identified, or those with a similar risk of neuromuscular disease
* Those who have participated in other clinical trials within 6 months of participating in clinical trials.
* Patients with severe pain in the knee joint other than angular deformity, instability, and index knee in the knee joint
* Patients with other tumors other than degenerative knee arthrosis
* Persons with systemic symptoms that may affect knee pain
* Pregnant and lactating women
A Study to Obtain Normal Values of Inflammatory Variables From Healthy Subjects

Smoking induces an inflammatory reaction in the airways which can ultimately result in persistent damage and the development of a Chronic Obstructive Pulmonary Disease (COPD). However, not all subjects who smoke end up with COPD. After long-term smoking, approximately 20% of subjects develop COPD. At this time, it is unclear why some subjects develop COPD, whereas others maintain a normal lung function.

In addition, smoking has important consequences in asthma. Patients with asthma who smoke have a more severe asthma and more often experience an asthma exacerbation. In addition, it has been shown that inhaled corticosteroids are less effective in smoking asthmatics.

With this research project, the researchers will investigate the effects of smoking on the airways. To this end, the researchers will compare markers of airway inflammation, lung function and symptoms between healthy smokers and non-smokers of varying age. In addition, the researchers will compare those healthy subjects with patients with asthma and COPD which are characterized in earlier studies.


Eligibility Criteria:
Inclusion Criteria:

* Have not smoked during the last year.
* Have never smoked for as long as a year.
* Have \< 0.5 packyear.

Exclusion Criteria:

* Persons who used inhaled or oral corticosteroids during \>5 years, or within the last 5 years.
* FEV1 \<1.2 L
* A subject is not eligible to enter and participate if he does not agree that we inform his general practicioner about participation in the study and also about any unexpected finding during the study.
* Upper respiratory tract infection (e.g. colds), within 2 months.
* Pregnancy, or the possibility of being pregnant (i.e. women who do not use adequate anticonception as judged by the investigator).
* Malignancy within the past 5 years (except for squamous or basal cell carcinoma of the skin that has been treated with no evidence of recurrence).
* Signs or symptoms of any other concomitant disease that, in the eyes of the investigator, can interfere with the study results.
* Known recent substance abuse (drug or alcohol).
* Claustrophobia.
Observational Study With InnoLet® in Daily Clinical Practice

This study is conducted in Asia. The aim of this study is to review the efficacy and safety of insulin treatment with InnoLet® in daily clinical practice.


Eligibility Criteria:
Inclusion Criteria:

* Diabetes mellitus (Type 1 or type 2)
* Need insulin treatment
Patient Empowerment for Major Surgery Preparation @ Home

The PAPRIKA project is a feasibility study with duration of 10 months. The aim of the study is to recruit 25 patients over the age of 65 who will undergo tumor-related esophagectomy and will follow a prehabilitation program to prevent postoperative complications and improve patient-centric complications and patient-centered outcomes.

After determination of the oncologic treatment plan in the tumor board and functional assessment, patient will undergo an interdisciplinary assessment , which will be performed by the PAPRIKA team consisting of physiotherapists, internists/geriatricians, speech and occupational therapists, nutritionists and surgeons.

On the basis of this interdisciplinary assessment an individualized catalog of procedures will be created. Patient have to follow to this catalog of procedures until surgery. Procedures catalog contains behavioral changes, physical training, nutritional counseling, conditioning of pulmonary function and optimization of drug treatment of underlying diseases.

The individual treatments will be weekly reevaluated and if necessary the procedures will be adjusted by treatment teams.

The prehabilitation procedures will be communicated with the patient via a smartphone app, which is specially developed for the prehabilitation program. The implementation will be documented.

The primary aim of this study is to evaluate the compliance of the patients regarding to the prescribed procedures and the use of the smartphone app (feasibility).

As secondary aim postoperative outcome will be compared with the results of a historical cohort for quality control.


Eligibility Criteria:
Inclusion Criteria

* Patients ,undergoing transthoracic esophagectomy (Ivor Lewis), in ≥ 4 weeks
* Age \>65 years
* American Society of Anaesthesiologists - Score: 2-3
* Ability to give informed consent
* Written informed consent

Exclusion Criteria:

* Planned operation in less than 4 weeks after enrollment
* Urgent surgery indication
* Patients with good to excellent general and nutritional condition (0 points in the pre-screening of the modified NRS OR 1 point in the pre-screening and \<2 points in the main screening).
* Patients deemed by the PAPRIKA team to be physically or mentally incapable of completing the exercise program.
Long-term Safety Follow-up of Participants Exposed to the Candidate Ebola Vaccines Ad26.ZEBOV and/or MVA-BN-Filo

The purpose of the study is to assess the long-term safety profile of Ad26.ZEBOV and MVA-BN-Filo in participants previously exposed to these vaccines in Phase 1, 2, or 3 clinical studies.

This is a multi-country, prospective, long-term clinical safety study for collection of serious adverse events and pregnancy outcomes following administration of Ad26.ZEBOV and/or MVA-BN-Filo vaccines among participants who were enrolled in Phase 1, 2 or 3 clinical studies. The safety data will be collected in 3 cohorts; Cohort 1- adult and pediatric participants that received Ad26.ZEBOV and/or MVA-BN-Filo in Phase 1, 2 or 3 clinical studies (adults, adolescents and children), Cohort 2- Female participants who became pregnant with estimated conception within 28 days after vaccination with MVA-BN-Filo or within 3 months after vaccination with Ad26.ZEBOV will be followed to the end of their pregnancy for pregnancy outcomes (Cohort 2). After the end of pregnancy, female participants will continue to be followed in Cohort 1. Cohort 3 - children born to female participants exposed to Ad26.ZEBOV and/or MVA-BN-Filo who became pregnant with estimated conception within 28 days after vaccination with MVA-BN-Filo or within 3 months after vaccination with Ad26.ZEBOV. Safety data will be collected on all consenting participants.

Eligibility Criteria:
Inclusion Criteria:

* Male or female who participated in a Phase 1, 2 or 3 clinical study with Human adenovirus serotype 26 (Ad26) expressing the Ebola virus Mayinga variant glycoprotein (Ad26.ZEBOV) and/or Modified Vaccinia Virus Ankara - Bavarian Nordic Filo-vector (MVA-BN-Filo) and has been exposed to Ad26.ZEBOV and/or MVA-BN-Filo (Cohort 1)
* Female who participated in a Phase 1, 2 or 3 clinical study with Ad26.ZEBOV and/or MVA-BN-Filo and became pregnant with estimated conception within 28 days after vaccination with MVA-BN-Filo or within 3 months after vaccination with Ad26.ZEBOV (Cohort 2)
* Child born to female participants exposed to Ad26.ZEBOV and/or MVA-BN-Filo in a Phase 1, 2, or 3 clinical study who became pregnant with estimated conception within 28 days after vaccination with MVA-BN-Filo or within 3 months after vaccination with Ad26.ZEBOV (Cohort 3)
* Must sign an informed consent form for the current study (or their legally acceptable representative must sign) indicating that he or she understands the purpose of, and procedures required for, the study and is willing to participate in the study (or let their child participate); Assent is also required of children capable of understanding the nature of the study (typically 7 years of age and older)

Exclusion Criteria:

* No exclusions beyond those that are not meeting the inclusion criteria
Numerical Superiority and Inferiority Compared With Conventional Training on PTK and Executive Functions in Soccer

There is a great need to establish reliable evaluation and intervention protocols to improve the tactical component, decision making (DM) and procedural tactical knowledge (PTK) in soccer. Objectives: to determine the effects of a 12-week follow up numerical superiority and numerical inferiority tactical training program on PTK, which will be evaluated by calculating offensive, defensive and global effectiveness indexes (EI) of 24 amateur male soccer players, as well as the effect on their executive functions. Method: randomized controlled trial, with two groups in parallel, experimental group (EG) and control group (CG), with different measurements over time (pretest, intermediate test 1, intermediate test 2 and posttest).

Program characteristics: training frequency 5 times/week, 1 competition, frequency of stimulation of small side games (SSGs) and technical-tactical actions (ATT) of numerical superiority and inferiority 2 times/week, specific training time 30 to 42 minutes/session. The PTK will be evaluated through the Football Competence Observation System (FOCOS). Data analysis: Shapiro-Wilk will be applied and according to the results, the data will be summarized with means and standard deviation or with medians and interquartile ranges. A repeated measures design will be performed using ANOVA and MANOVA will also be performed. In addition, the assumption of homogeneity of the variances will be evaluated based on the Levene statistics. For executive functions, intragroup analysis will be performed using dependent Student's t-test or Wilcoxon. For intergroup analysis, t student for independent samples or U Mann Withney will be applied. Confidence intervals (CI95) and effect sizes for two tails will be reported, with an alpha (α) set at 0.05 and statistical power of 0.8 (1-β). Statistical significance (p≤0.05). SPSS version 27 and R version 4.0 will be used. Ethical aspects: the guidelines of the Declaration of Helsinki (2013) and the Ministry of Health and Social Protection (resolution 8430/1993) will be followed, this research is of minimal risk.

Eligibility Criteria:
Inclusion Criteria:

* Soccer players belonging to a soccer club.
* Who play the role of field players (all except goalkeepers).
* Who compete in the First B category of the Antioquia Soccer League in the 2023 season.
* Players between 17 and 26 years of age.
* Players with at least six months of experience in federated soccer.
* Players who do not present cognitive disorders that hinder learning, which can be identified through monitoring by coaches and/or tests conducted by the Neuropsychology staff.
* They must be affiliated to the contributory or subsidized health system.
* They must agree to participate in the study after knowing and signing the informed consent or assent, as appropriate.

Exclusion Criteria:

* Players with musculoskeletal disorders at the time of sample selection.
* Players recovering from injury.
"Immunomodulation in GWI (Phlebotomy)"

Gulf War Illness and deployed veterans of the 1990-1991 Persian Gulf War are invited to have a brief history and physical examination to determine their health status, complete questionnaires, then donate about 83 ml of blood. There is no follow-up

Gulf War Illness and deployed veterans of the 1990-1991 Persian Gulf War are invited to have a brief history and physical examination to determine their health status, complete questionnaires, then donate about 83 ml of blood. There is no follow-up.

Eligibility Criteria:
Inclusion Criteria:

* Kansas Criteria for GWI
* CDC criteria for CMI

Exclusion Criteria:

* Chronic medical or psychiatric disorder that may be responsible for symptoms of GWI
Dose Escalation Study of LGH447 in Japanese Patients With Relapsed and/or Refractory Hematologic Malignancies

This is a multi-center, open-label, dose escalation, Phase 1 study of oral LGH447 in Japanese patients with relapsed and/or refractory multiple myeloma for which no standard effective treatment options exist.

The study consists of a dose escalation part to estimate the maximum tolerated dose and/or the recommended dose for expansion and a dose expansion part to further assess safety and preliminary anti-cancer activity of LGH447 at the maximum tolerated dose and/or the recommended dose for expansion.


Eligibility Criteria:
Inclusion Criteria:

-Confirmed diagnosis of relapsed and/or refractory MM for which no standard effective treatment options exist.

Exclusion Criteria:

-Uncontrolled cardiovascular condition, including ongoing cardiac arrhythmias, congestive heart failure, angina, or myocardial infarction within the past 6 months.
Specific Role of Nurse in a Mobile Palliative Care Team (EMSP): Real Autonomy or Utopia

A bibliographic search carried out by the investigators demonstrated that there are few studies or data relating to the role and place of a State Registered Nurse (IDE) in a Mobile Palliative Care Team (EMSP) concerning the collection and the analysis of the needs expressed when formulating an evaluation request by the EMSP. The IDE collects, questions, analyzes needs and initiates an evaluation with the patient or, failing that, advises and/or redirects. This first necessary step before the overall evaluation led the investigators to question the autonomy of the IDE in an EMSP and to research what are the representations of an IDE in this role of collecting and analyzing needs. when making such a request?

The aim of this research is to explore the professional practices of nurses within other PMSCs in order to analyze them and move towards improving patient care.


Eligibility Criteria:
Inclusion criteria:

* State-certified nurse working in EMSP with intra- and extra-hospital activity in a CHRU or CHU.
* Subject having given their consent for the reuse of their data for the purposes of this research

Exclusion criteria:

* Subject having expressed opposition to participating in the study